A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of novel drug targets.
In a study published today in Nature Genetics a group of international scientists led by deCODE Genetics in Iceland, a subsidiary of Amgen Inc., analyzed genetic data from over 1.3 million participants of which 80 thousand had migraine. The scientists focused on detecting sequence variants associated with the two main subtypes of migraine: migraine with aura (often referred to as classical migraine) and migraine without aura. The results highlight several genes that affect one of these migraine subtypes over the other, and point to new biological pathways that could be targeted for therapeutic developments.
Migraine is among the most common chronic pain disorders worldwide, with up to 20% of adults affected. Although recent advances have been made in studies of the genetics and underlying biology of migraine and new treatments recently developed that are effective for many migraine sufferers, they do not work for all types of migraine
The study revealed associations with 44 variants, 12 of which are novel. Four novel migraine with aura associations were revealed and 13 variants were associated primarily with migraine without aura. Of particular interest were three rare variants with large effects pointing to distinct pathologies underlying different types of migraine. Thus, a rare frameshift variant in the PRRT2 gene confers a large risk of migraine with aura and with another brain disease, epilepsy, but not of migraine without aura. In SCN11A, a gene known to play a key role in pain sensation, scientists detected several rare loss-of-function variants associated with protective effects against migraine, while a common missense variant in the same gene is associated with a modest risk of migraine. Finally, a rare variant pointing to the KCNK5 gene confers large protection against severe migraine and brain aneurysms, either identifying a common pathway between the two diseases or suggesting that some cases of early brain aneurysms may be misclassified as migraine. „What makes our study unique is that it includes large datasets from sequenced individuals enabling detection of rare variants protecting against migraine, potentially opening an avenue for the development of novel drug targets,“ says Kari Stefansson, CEO of deCODE genetics.
The joint effort by the international research team was led by scientists at deCODE genetics in Iceland and included collaborating scientists from the Copenhagen Hospital Biobank and Danish Blood Bank Study, the HUSK study in Norway, the Intermountain Health study in the US, and data generated by large population-based studies from the UK Biobank and FinnGen.